BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, discovering a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.

Biotechnology

BenevolentAI

BenevolentAI's headquarters in United Kingdom

Joerg Moeller

Georgiana Neculae

Kenny Claes

Helen Long

Arpita Ray-Sinha

Wlad Stroukov

Anja Füllgrabe

Philip Clarke

Davy Suvee

Katie Sandford

Anna Fullerton-Batten

Ivan Griffin

Bruce Campbell

Nigel Shadbolt

Kenneth Mulvany

Peter Allen

Jeremy Sohn

Ian Nicholson

Description

People

Jobs